[1] LOCKRIDGE O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses[J]. Pharmacol Ther, 2015, 148:34-46. [2] PRADO M A M, MARCHOT P, SILMAN I. Preface:cholinergic mechanisms[J]. J Neurochem, 2017, 142:3-6. [3] PÉREZ-AGUILAR B, VIDAL C J, PALOMEC G, et al. Acetylcholinesterase is associated with a decrease in cell proliferation of hepatocellular carcinoma cells[J]. Biochim Biophys Acta, 2015, 1852(7):1380-1387. [4] CAMPOY F J, VIDAL C J, MUÑOZ-DELGADO E, et al. Cholinergic system and cell proliferation[J]. Chem Biol Interact, 2016, 259(Pt B):257-265. [5] KUMAR R, RAZAB S, PRABHU K, et al. Serum butyrylcholinesterase and zinc in breast cancer[J]. J Cancer Res Ther, 2017, 13(2):367-370. [6] DEBAY D R, REID G A, POTTIE I R, et al. Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease[J]. Alzheimers Dement (N Y), 2017, 3(2):166-176. [7] REALE M, COSTANTINI E, DI NICOLA M, et al. Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients:implication in peripheral inflammation[J]. Sci Rep, 2018, 8(1):1319. [8] GABRIEL A J, ALMEIDA M R, RIBEIRO M H, et al. Influence of butyrylcholinesterase in progression of mild cognitive impairment to Alzheimer's disease[J]. J Alzheimers Dis, 2018, 61(3):1097-1105. [9] 段海波, 王金勇, 申元英, 等. 阿托品对氧乐果中毒小鼠胆碱酯酶急性重活化作用[J]. 职业与健康, 2016, 32(6):755-757. [10] BENEK O, MUSILEK K, HOROVA A, et al. Preparation, in vitro screening and molecular modelling of monoquaternary compounds related to the selective acetylcholinesterase inhibitor BW284c51[J]. Med Chem, 2014, 11(1):21-29. [11] 朱龙, 许航, 叶燕锐, 等. 丁酰胆碱酯酶抑制剂对急性高血脂小鼠模型血脂的影响[J]. 中华实验外科杂志, 2016, 33(7):1797-1799. [12] 魏红. 高血脂家兔丁酰胆碱酯酶和血脂的相关性研究[D]. 广州:华南理工大学, 2015. |